SynthesisFrontiers in oncology2021
Efficacy and Safety of Radiofrequency Ablation for Breast Cancer Smaller Than 2 cm: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Thermal ablation for early-stage breast cancer: cryoablation, microwave ablation, radiofrequency ablation, high-intensity focused ultrasound ablation, and laser ablation - a systematic review.Breast (Edinburgh, Scotland) · 2026Pooled it
- MRI-based assessment for optimal breast cancer local therapy in the era of BI-RADS v2025.Japanese journal of radiology · 2026Review
- Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer.Breast cancer research and treatment · 2026Article
- Emerging advances in non-surgical ablation for early-stage breast cancer.Japanese journal of radiology · 2026Review
- Radiofrequency ablation for early breast cancer: from local technique to system-based surgical therapy.Frontiers in oncology · 2026Review
- Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy.International journal of nanomedicine · 2025Review
- Effects of low-frequency ultrasound combined with microbubbles on breast cancer xenografts in nude mice.Global health & medicine · 2024Article
- Shear-Wave Elastography Gradient Analysis of Newly Diagnosed Breast Tumours: A Critical Analysis.Diagnostics (Basel, Switzerland) · 2024Article
- Minimally invasive treatment of early, good prognosis breast cancer-is this feasible?The British journal of radiology · 2024Review
- Magnetic resonance imaging-guided radiofrequency ablation of breast cancer: a current state of the art review.Diagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- Intraductal photothermal ablation: a noninvasive approach for early breast cancer treatment and prevention.Theranostics · 2024Article
- Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects.Cancers · 2023Review
- Interventional oncology update.European journal of radiology open · 2022Article
- Ablative Therapies for Breast Cancer: State of Art.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the efficacy and safety of radiofrequency ablation (RFA) of breast cancer smaller than 2 cm.
methodsA systematic search was conducted in the PubMed and EMBASE databases to identify published studies investigating the efficacy and safety of RFA for breast cancer smaller than 2 cm. The main outcomes were technical success rate of the ablation, complete ablation rate, complications and local recurrence. Secondary considerations were mode of anesthesia, pain tolerance, mean ablation time and surgical excision after ablation.
resultsSeventeen studies involving 399 patients and 401 lesions met the inclusion criteria. Nearly 99%(95%CI=0.98-1.00) of lesions achieved good technical success rate.Notably, 83.88% of the patients received RFA under general anesthesia (333/397) whereas 15.87% received RFA under local anesthesia (63/397). Of the 63, 98.41% tolerated the pain associated with the procedure. Majority of patients (65.74%, 261/397) underwent surgical excision of the tumor after ablation whereas in a few patients (34.26%, 136/397), the tumor tissue was retained in the breast after ablation. Complete ablation was achieved in 96% of patients for a mean time of 15.8 minutes (95%CI=0.93-0.99). Overall, only 2% (95%CI=0.01-0.04) of the individuals developed complications. Skin burns (2.02%, 8/397) were the most common complications. There was no local recurrence after a median follow-up of 27.29 months, whether or not they underwent surgical resection following RFA.
conclusionThe results show that RFA for breast cancer smaller than 2 cm is safe and effective. However, prospective studies are needed to validate this conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.